This topic highlights President Trump's scientifically dubious remarks on autism and COVID-19, including unproven warnings about Tylenol and its perceived link to autism, which has led to a crisis for Tylenol's manufacturer Kenvue and scrutiny over expert witness payments in related lawsuits.

• On Covid and Autism, Trump Strays From the Science — The New York Times Health -
• Harvard Dean Was Paid $150,000 as an Expert Witness in Tylenol Lawsuits — The New York Times Health -
• Kenvue, the Company Behind Tylenol, Tries to Navigate Its Latest Crisis — The New York Times Health -

• For Trump, Who Has ‘Strong Feelings’ About Autism, the Issue Is Personal — The New York Times Health -
• Trump Issues Warning Based on Unproven Link Between Tylenol and Autism — The New York Times Health -

This topic focuses on the FDA's controversial approval of an existing drug for autism treatment, which has altered the agency's review process and spurred public interest in related over-the-counter supplements.

• F.D.A.’s Approval of a Drug for Autism Upends Review Process — The New York Times Health -

This topic details a judicial order for the N.I.H. to reinstate suspended research grants at U.C.L.A., addressing the Trump administration's termination of significant funding for the university.

• Judge Orders N.I.H. to Restore Suspended Research Grants at U.C.L.A. — The New York Times Health -

This topic brings to light the alarming suicide risk in ICE detention centers, exacerbated by inadequate mental health care for immigrant detainees, as reported by advocates.

• ‘People Are Losing Hope’: Suicide Risk Is Rife in ICE Detention Centers — The New York Times Health -